The standardization of a biochemical laboratory determination of a multiple
myeloma
Tichý M.1, Friedecký B.1, Vávrová J.1, Maisnar V.2, Palička V.1, Hájek R.3, Novotná H.4, Čermáková Z. 4, Jarolímková E.5, Benáková H.5, Hachová L.5, Bezdíčková D. 5, Vogtová D.6, Kopřivová H.6, Čechák P.6, Kouřil F.7, Zábranská A.7, Ženková J.8, Slabý P. 8
1Ústav klinické biochemie a diagnostiky LF UK a FN, Hradec Králové 2II. interní klinika, Oddělení klinické hematologie LF UK a FN, Hradec Králové 3Hematoonkologická klinika FN a LF MU, Brno – Bohunice, 4Oddělení klinické biochemie a hematologie FN, Brno – Bohunice 5Ústav klinické biochemie a laboratorní diagnostiky, VFN Praha 6Ústav biochemie a patobiochemie, FNKV, Praha 7Oddělení klinické biochemie, FN Olomouc 8Ústav klinické biochemie a hematologie LF UK a FN Plzeň |
|
Fulltext
Summary:
Objective: The standardization of the biochemical measurement procedures in a blood serum of patients with multiple
myeloma concerning an implementation of a new international prognostic index, which uses only two laboratory
markers, albumin and beta-2 microglobulin.
Design: The study compares the results of albumin, beta-2 microglobulin and partly the concentration of paraproteins
from six cooperative centres, which provide treatment of the multiple myeloma in the Czech Republic, in order to
integrate these investigations.
Material and Methods: The laboratories of university hospitals – General University Hospital of Prague, University Hospital
of Prague–Vinohrady, Hradec Králové, Olomouc, Brno–Bohunice and Plzeň have been chosen for the implementation of
the study. Each control serum sample was divided into six equal parts and was frozen at –80 oC. The transportation of the
samples to the single laboratory was performed in a frozen box and the samples were stored at least at –70 oC till the date
of determination. The whole project lasted two years and step by step it was divided into three periods (2003–2005). In the
first period the determination of albumin was standardized and the unsuitability of the RIA method determination of beta-2
microglobulin with other methods was proved. In the second period the determination of beta-2 microglobulin was
standardized successfully, but because of some technical defects it was not possible to use the samples for the determination
of paraproteins concentration. In the third period of the study 12 samples of blood serums were distributed, always
with one monoclonal immunoglobulin to determine its concentration. Results: The determination of albumin is well standardized, a confidence interval for 95% is between 1.3–3.0% (tolerance
limit for external quality assessments up to 9%). The unification of methods managed a comparability of the
results of beta-2 microglobulin. The variation coefficient is to the 15% (tolerance limit derived from biological variation
of this analyte is up to 15.5%). The determination of monoclonal immunoglobulins concentration confirmed the known
experience that it is impossible to consolidate the determination because of many partial uncertain steps. Nevertheless
the study showed clinical usability and analytical comparability of the results from the single centers with the concentration
of paraproteins over 20 g/l.
Conclusion: The determination of albumin is well standardized and the results from all laboratories are comparable.
The determination of beta-2 microglobulin after a methodical unification provides comparable results without any
significant differences. The determination of the monoclonal immunoglobulins concentration provided comparable
results especially in concentrations higher than 20 g/l. This determination is mostly questionable, but it is concerned to
monitor relative changes by every laboratory, therefore the harmonization of the results has not been relevant of
feasible so far.
Key words:
multiple myeloma, monoclonal immunoglobulin, albumin, beta-2 microglobulin, standardization.
|